Articles From: Lifshitz Law Firm Announces Investigation of Achillion Pharmaceuticals, Inc., ARIAD Pharmaceuticals, Inc., Brazil Fast Food Corp. and Camco Financial Corporation to Ligand to Report Fourth Quarter Results on February 11th


2013/12/19
Wells Fargo & Company, America’s largest mortgage lender, and NeighborWorks America, a national nonprofit organization which creates opportunities for people to live in affordable homes and improve their lives, today announced more than 5,000 low- to moderate-income adults have become homeowners with the help of homebuyer education and down-payment assistance offered through LIFT programs.
Sign-up for LIFT Programs Help 5,000 People Achieve Dream of Homeownership investment picks
2013/8/26
DALLAS , Aug.
Sign-up for LIG Assets, Inc. Announces Share Purchase Program investment picks
2013/10/7
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) has opened an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) and has obtained FDA approval to initiate clinical development for its Glucagon Receptor Antagonist program with LGD-6972 for the treatment of type 2 diabetes mellitus.
Sign-up for Ligand Announces FDA Acceptance of Investigational New Drug Application for Glucagon Receptor Antagonist Program investment picks
2014/3/11
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) presented today at the Roth Capital Conference in Dana Point, California, where it reviewed its business and financial highlights, its unique R&D model and selected un-partnered programs, and provided partnering case studies.
Sign-up for Ligand Announces Highlights from Presentation at the 26th Annual Roth Capital Conference investment picks
2013/11/14
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) reviewed its business model, growth opportunities, portfolio of partnered assets and unpartnered development programs, as well as its 2014 to 2016 financial outlook at an Analyst Day event held earlier today in Chicago.
Sign-up for Ligand Announces Highlights from Today’s Analyst Day Event investment picks
2013/12/9
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that data from preclinical studies on its granulocyte colony stimulating factor (G-CSF) receptor agonist program were featured in a poster presentation today at the 55 th Annual Meeting of the American Society of Hematology (ASH) in New Orleans.
Sign-up for Ligand Announces Positive Preclinical Data on Small-Molecule G-CSF Receptor Agonist at the 55th Annual Meeting of the American Society of Hematology investment picks
2014/3/17
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that it has earned a $1 million milestone payment as a result of the recent U.S. Food and Drug Administration (FDA) approval of Merck’s NOXAFIL® (posaconazole) injection (18 mg/mL). This is a new Captisol®-enabled formulation of NOXAFIL for intravenous (IV) use.
Sign-up for Ligand Earns $1 Million Milestone Payment Triggered by FDA Approval of Merck’s NOXAFIL® (posaconazole) Injection for Intravenous Use, a New Captisol-enabled Formulation investment picks
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered a global license agreement with CURx Pharmaceuticals, Inc. for the development and commercialization of Ligand’s Captisol-enabled™ Topiramate Injection for the treatment of partial onset or primary generalized tonic-clonic seizures in hospitalized epilepsy patients who are unable to take oral topiramate.
Sign-up for Ligand Enters Global License Agreement with CURx Pharmaceuticals, Inc. for Captisol-EnabledTM Topiramate Injection investment picks
2013/11/12
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced the initiation of a Phase 1 clinical trial with the Company’s glucagon receptor antagonist LGD-6972 for the treatment of type 2 diabetes.
Sign-up for Ligand Initiates Phase 1 Trial with Glucagon Receptor Antagonist for Type 2 Diabetes investment picks
2014/2/3
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that the U.S. Food and Drug Administration (FDA) has granted its partner GlaxoSmithKline plc (LSE:GSK) Breakthrough Therapy designation for Promacta®/Revolade® (eltrombopag) for the treatment of cytopenias in patients with severe aplastic anemia (SAA) who have had insufficient response to immunosuppressive therapy.
Sign-up for Ligand Partner GlaxoSmithKline Gains FDA Breakthrough Therapy Designation for Promacta®/Revolade® for Severe Aplastic Anemia investment picks
2014/2/28
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner GlaxoSmithKline plc (LSE:GSK) announced today the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for Promacta ® (eltrombopag) for the treatment of cytopenias (a reduction in blood cells) in patients with severe aplastic anaemia (SAA) who have had an insufficient response to immunosuppressive therapy (IST). SAA is a rare disorder in which the bone marrow fails to make enough new blood cells.
Sign-up for Ligand Partner GlaxoSmithKline Submits U.S. Regulatory Application for Promacta® (eltrombopag) for Severe Aplastic Anaemia investment picks
2013/9/24
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner GlaxoSmithKline plc (LSE:GSK) (NYSE:GSK) announced today that the European Commission has granted an additional indication for Revolade™ (eltrombopag) as a treatment for low platelet counts (thrombocytopenia) in adult patients with chronic hepatitis C infection, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon (IFN)-based therapy.
Sign-up for Ligand Partner GSK Receives Marketing Authorization from the European Commission for Additional Revolade™ (Eltrombopag) Indication as the First Approved Treatment for Chronic Hepatitis C-Associated Thrombocytopenia investment picks
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner Pfizer received approval today from the U.S. Food and Drug Administration (FDA) for DUAVEE TM (conjugated estrogens/bazedoxifene), for the treatment of moderate-to-severe vasomotor symptoms (VMS) associated with menopause and the prevention of postmenopausal osteoporosis.
Sign-up for Ligand Partner Pfizer Receives FDA Approval for DUAVEETM for the Treatment of Moderate-to-Severe Vasomotor Symptoms (Hot Flashes) Associated with Menopause and the Prevention of Postmenopausal Osteoporosis investment picks
NEW YORK , Nov.
Sign-up for Ligand Pharmaceuticals Set to Join the S&P SmallCap 600 investment picks
2014/2/11
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and 12 months ended December 31, 2013, and provided an operating forecast and program updates.
Sign-up for Ligand Reports Fourth Quarter and Full Year 2013 Financial Results investment picks
2013/8/1
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the second quarter and six months ended June 30, 2013, and provided an operating forecast and program updates.
Sign-up for Ligand Reports Second Quarter Financial Results investment picks
2013/10/30
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the third quarter and nine months ended September 30, 2013, and provided an operating forecast and program updates.
Sign-up for Ligand Reports Third Quarter Financial Results investment picks
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will host an Analyst Day in Chicago on Thursday, November 14, 2013 from 9:30 a.m. to 11:30 a.m. Central Time (7:30 a.m. to 9:30 a.m. Pacific Time). The event will feature presentations pertaining to the Company’s business and pipeline programs.
Sign-up for Ligand to Host Analyst Day on November 14th in Chicago investment picks
2014/2/26
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that John Higgins, President and Chief Executive Officer and Matt Foehr, Chief Operating Officer and Executive Vice President of Ligand, will present at the 26th Annual Roth Conference on Tuesday, March 11, 2014 at 1:30 p.m. Pacific (4:30 p.m. Eastern Time). The conference takes place at The Ritz-Carlton in Dana Point, California.
Sign-up for Ligand to Present at the 26th Annual Roth Conference on March 11 investment picks
2014/2/10
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that it has earned $1 million commercial milestone payment from Onyx Pharmaceuticals (a subsidiary of Amgen, Inc.). The milestone payment was triggered by the achievement of over $250 million of annual product sales of Kyprolis in 2013.
Sign-up for Ligand to Receive $1 Million Kyprolis® Commercial Milestone Payment from Onyx Pharmaceuticals investment picks
2014/1/29
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report fourth quarter 2013 financial results on February 11, 2014.
Sign-up for Ligand to Report Fourth Quarter Results on February 11th investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Lifshitz Law Firm Announces Investigation of Achillion Pharmaceuticals, Inc., ARIAD Pharmaceuticals, Inc., Brazil Fast Food Corp. and Camco Financial Corporation to Ligand to Report Fourth Quarter Results on February 11th
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity